| Literature DB >> 35898820 |
Jianying Song1,2, Lixin Hu1,2, Bo Liu2, Nan Jiang3, Houqiang Huang4, JieSi Luo3, Long Wang3, Jing Zeng3, Feihong Huang3, Min Huang5, Luyao Cai2, Lingyu Tang2, Shunli Chen2, Yinyi Chen2, Anguo Wu3, Silin Zheng4, Qi Chen1,2,6,7.
Abstract
Poor wound healing in individuals with diabetes has long plagued clinicians, and immune cells play key roles in the inflammation, proliferation and remodeling that occur in wound healing. When skin integrity is damaged, immune cells migrate to the wound bed through the actions of chemokines and jointly restore tissue homeostasis and barrier function by exerting their respective biological functions. An imbalance of immune cells often leads to ineffective and disordered inflammatory responses. Due to the maladjusted microenvironment, the wound is unable to smoothly transition to the proliferation and remodeling stage, causing it to develop into a chronic refractory wound. However, chronic refractory wounds consistently lead to negative outcomes, such as long treatment cycles, high hospitalization rates, high medical costs, high disability rates, high mortality rates, and many adverse consequences. Therefore, strategies that promote the rational distribution and coordinated development of immune cells during wound healing are very important for the treatment of diabetic wounds (DW). Here, we explored the following aspects by performing a literature review: 1) the current situation of DW and an introduction to the biological functions of immune cells; 2) the role of immune cells in DW; and 3) existing (or undeveloped) therapies targeting immune cells to promote wound healing to provide new ideas for basic research, clinical treatment and nursing of DW.Entities:
Keywords: diabetic wounds; immune cells; inflammation; targeted therapy; wound healing
Year: 2022 PMID: 35898820 PMCID: PMC9309318 DOI: 10.2147/JIR.S371939
Source DB: PubMed Journal: J Inflamm Res ISSN: 1178-7031
Introduction to the Biology of Immune Cells
| Cell Type | Origin | Key Markers | Clinical Subtypes | Production | General Functions | References |
|---|---|---|---|---|---|---|
| Neutrophils | Myeloid lineage progenitor cells | Human: CD66b and CD16 | N1 | Antimicrobial peptides (AMPs, including cathelicidins and β-defensins), ROS, and cytotoxic enzymes such as elastase and myeloperoxidase | Resisting microbial invasion and promoting wound healing via phagocytosis, degranulation and the release of NETs | [ |
| Macrophages | Monocytes | Human: CD11b, CD36, CD206, CD204 or CD68 | M1 | IL-1, IL-6, IL-8, TNF-α, IL-12, IL-23, Arg-1, IL-4, IL-10, IL-13, Ym1, and TGF-β1 | Promotion and inhibition of inflammation | [ |
| MCs | Hematopoietic stem cells in the bone marrow | Tryptase | MCTC | TNF-α, CXCL2, IL-1, IL-8, VEGF, CXCL16, Endothelin-1, GM-CSF, IL-8, and MCP-1 | Regulating inflammation, tissue remodeling, allergic reactions, wound healing, heart function, immune defense and angiogenesis, among other processes | [ |
| Dendritic cells | Hematopoietic stem cells | Human: Langerin, CD11c, CD141, CLEC9A (C-type lectin domain family 9 member A) or MHC II | cDC1s | IFN-I and IL-33 | Participation in the immune response via antigen presentation and IFN-I production | [ |
| T lymphocyte | Multipotent blood progenitors | CD8, CD4, FoxP3, CD3 or ζ-chain | CD4+ T helper cells, | Histamine, heparin and other proteoglycans, granule-associated proteases, leukotrienes and prostaglandins | Destruction of infected cells; | [ |
Abbreviations: AMPs, antimicrobial peptides; NETs, neutrophil extracellular traps; MCs, mast cells; CLEC9A, C-type lectin domain family 9 member A; IRF8, interferon-regulatory factor 8.
Figure 1Deregulated immune cells impair DW healing. Immune cells play an important role in the difficult-to-heal pathological process of DW. In DW, continuous infiltration of neutrophils, imbalance of M1 and M2 macrophages, increased degranulation of MCs, and dysregulation of DCs and T cells jointly lead to the continuous release of inflammatory factors, triggering inflammatory cascades, vascular maturation disorders, and decreased collagen deposition, which in turn cause DW to end up in a difficult or even non-healing ending.
Therapies Targeting Immune Cells in Wound Healing
| Treatment Strategies | Examples | Targeted Cells or Genes | Effect on Skin Wound Healing | Wound Healing Outcomes/Results | References |
|---|---|---|---|---|---|
| Drug | Clarithromycin | Neutrophils | Upregulation of LL-37 on NET structures, enhancement of antibacterial defenses and improvement of the wound healing capacity of fibroblasts | Wound closure is accelerated | [ |
| Quercetin, Astragaloside IV and Docosahexaenoic acid | Macrophages | Restoration of the M1/M2 balance of macrophages | Wound closure is accelerated | [ | |
| Fms-like tyrosine kinase-3 ligand | Dendritic cells | Increases the number of dendritic cells | Wound closure is accelerated | [ | |
| Insulin | Neutrophils and macrophages | Reestablishment of damaged neutrophil phagocytic function and induction of macrophage polarization from the M1 to M2 phenotype | Wound closure is accelerated | [ | |
| Natural compounds | yi medicine “yi bu a jie” extract | Neutrophils | Inhibits inflammatory neutrophil exudation and promotes the growth of granulation tissue and proliferation of fibroblasts | Wound closure is accelerated | [ |
| Fermented papaya preparation | Macrophages | Promotes the effective aggregation of monocytes and improve the function of macrophages | Wound closure is accelerated | [ | |
| Q. infectoria | Macrophages | Inhibits the Set7/NF-kB pathway in macrophages to promote the normalization of the inflammatory microenvironment in DW | Wound closure is accelerated | [ | |
| Hsian-tsao | Macrophages | Enhances macrophage-mediated phagocytosis and inhibits the release of inflammatory mediators | Wound closure is accelerated | [ | |
| Propolis | Macrophages | Inhibits neutrophil and macrophage infiltration | Wound closure is accelerated | [ | |
| G. procumbens | MCs | Increases the accumulation and migration of MCs | Wound closure is accelerated | [ | |
| Physical therapy | Hyperbaric oxygen therapy | Neutrophils | Reduces the cell adhesion function of the neutrophilic integrins α4β1 and β2 | Wound closure is accelerated | [ |
| Photobiomodulation | MCs | Reduces the total numbers of MCs | Wound closure is accelerated | [ | |
| Different types of electrical stimulation | Neutrophils, macrophages, MCs, and lymphocytes | Reduces the number of immunocytes and cytokine levels | Shortens the inflammation phase | [ | |
| ESWT | Macrophages | Increases the uptake of apoptotic cells and healing-associated cytokine and growth factor gene expression, and modulates macrophage morphology to that suggestive of macrophage activation | Wound closure is accelerated | [ | |
| Biomaterials | HA-JK1 hydrogels | Macrophages | Remodels the macrophage phenotype | Wound closure is accelerated | [ |
| HA@MnO2/FGF-2/Exos hydrogel | Macrophages | Release of M2-derived exosomes and FGF-2 growth factor stimulates angiogenesis and epithelization | Wound closure is accelerated | [ | |
| Intelligent dressings | Neutrophils | Binds specifically to human neutrophil elastase present in wound fluid | Provides indications for clinical treatment | [ | |
| KSiNPs | Macrophages | Reprogramming of macrophages with particle-induced clustering of mannose receptors | Wound closure is accelerated | [ | |
| RNAi | Silencing of Keap1 expression by topically delivered siRNA | Keap1 | Inhibiting oxidative stress by inhibiting the combination of Keap1 and Nrf2 | Wound closure is accelerated | [ |
| Silencing of p53 expression through the topical delivery of siRNAs | Tumor protein p53 | Inhibition of apoptosis and stimulation of the HIF1a-dependent pathways | Wound closure is accelerated | [ | |
| Silencing of PHD expression through the topical delivery of siRNAs | PHD | Increased expression of HIF1α and VEGFα, improving fibroblast proliferation | Wound closure is accelerated | [ | |
| Engineered miR-31 exosomes | miR-31-5p | Enhanced angiogenesis, fibrogenesis and re-epithelization | Wound closure is accelerated | [ | |
| Stem cells | CCR2-MSCs | Macrophages, T cells | Inhibition of monocyte infiltration, remodeling the inflammatory properties of macrophages, and promotion of Treg cell accumulation | Wound closure is accelerated | [ |
| MSC-derived exosomes | Macrophages | Increased ratio of M2 polarization to M1 polarization through the upregulation of PTEN expression and inhibition of AKT phosphorylation | Wound closure is accelerated | [ | |
| MSCs | Macrophages | Activation of corneal epithelial stem/progenitor cells and acceleration of M2 macrophage polarization | Wound closure is accelerated | [ | |
| ASCs | Macrophages | Inhibition of inflammation and macrophage infiltration | Promotion of the proliferation and migration of skin fibroblasts, and wound closure is accelerated | [ |
Abbreviations: NET, neutrophil extracellular trap; DW, diabetic wounds; MCs, mast cells; ESWT, extracorporeal shockwave therapy; siRNA, small interfering RNA; KSiNPs, KGM-modified SiO2 nanoparticles; PHD, HIF-prolyl hydroxylase domain; CCR2-MSCs, C–C motif chemokine receptor 2-engineered mesenchymal; MSCs, mesenchymal stem cell; ASCs, adipose stem cells.